A M ATTR of Time:

Expert Perspectives and Case Study on Suspicion, Diagnosis, and Treatment of Transthyretin Cardiac Amyloidosis*

*Also known as transthyretin amyloid cardiomyopathy (ATTR-CM).

Next Program:
Tuesday, 30 September 2025 - 12:15 pm CST

(Note that the webinar cannot be viewed on a mobile device, please use a computer or tablet.)

Finding and Treating ATTR Cardiac Amyloidosis*: Clinical Trial and Real World Data for a Treatment Option

Expert-led case study leveraging a real patient case, with follow-up post diagnosis and treatment initiation.

INDICATION

Important Safety Information

INDICATIONS

VYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Please see Full Prescribing Information including Patient Information.
Adverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.
Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.


Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatchor call 1-800-FDA-1088